Ivermectin is a single molecule, but it reaches patients in several very different forms — oral tablets in 3mg, 6mg, and 12mg strengths, a 1% topical cream, a 0.5% topical lotion, and veterinary preparations that were never meant for human use at all. These are not interchangeable packaging choices. The route a drug takes into the body determines where it goes, how much of it gets there, and what it can and cannot treat. This article explains what each formulation actually is, what legitimate evidence supports its use, what it looks like, and why swapping one form for another can change — or eliminate — the intended outcome.

A Molecule Discovered in the Soil

Ivermectin descends from avermectin, a compound isolated from Streptomyces avermitilis, a bacterium found in a soil sample collected in Japan in the 1970s. The discovery, credited to Satoshi Ōmura and further developed by William Campbell, was significant enough to earn both scientists a share of the 2015 Nobel Prize in Physiology or Medicine. It is worth pausing on that: one of modern medicine's most important antiparasitic drugs came from ordinary dirt, refined through careful, patient laboratory work. For readers who see providence in the created order, it is a fitting reminder that the natural world has yielded remedies long before anyone understood the chemistry behind them.

Ivermectin works by binding to glutamate-gated chloride channels found in the nerve and muscle cells of invertebrates — parasitic worms, mites, and insects — causing paralysis and death of the organism. Mammals do not have these particular channels in the same way, and the drug does not cross an intact human blood-brain barrier in meaningful amounts at approved doses, which is why it has an unusually favorable safety record when used as directed for its approved indications.

Oral Tablets: 3mg, 6mg, and 12mg

Oral ivermectin is a systemic treatment — it enters the bloodstream through the gut and travels throughout the body. This is essential for its approved uses, because the parasites it targets in these indications live inside tissue or migrate through it. The U.S. Food and Drug Administration has approved oral ivermectin for two indications: intestinal strongyloidiasis and onchocerciasis (river blindness), both caused by parasitic worms. It is also used off-label, at established dosing, for scabies in some clinical contexts, particularly crusted scabies or outbreaks in institutional settings, based on smaller trials and clinical experience rather than large FDA-reviewed programs.

In the United States, the FDA-approved oral strengths are 3mg and 6mg tablets, dosed by body weight — typically in the range of 150 to 200 micrograms per kilogram for onchocerciasis, given as a single dose that may be repeated depending on the condition. A 12mg tablet is not a standard FDA-approved U.S. strength; it is widely manufactured and sold in other countries, including India, under different national regulatory systems, and is commonly encountered by patients researching the drug online. Anyone in the U.S. sourcing 12mg tablets outside a licensed pharmacy should understand they are outside the FDA-regulated supply chain, with the quality-control assurances that come with it.

Physically, generic ivermectin tablets are small, white to off-white, round or oval, and usually scored or imprinted with the manufacturer's marking and strength. There is no dramatic difference in appearance between 3mg, 6mg, and 12mg tablets beyond size and imprint, which is precisely why dosing errors matter — a tablet cannot be identified safely by sight alone. In the U.S., a short course of generic oral ivermectin for an approved indication is inexpensive by prescription-drug standards, typically a modest out-of-pocket cost at a retail pharmacy; international generic 12mg tablets are often sold even more cheaply, though price should never be the deciding factor over a documented, regulated supply.

Topical Cream and Lotion: A Different Job Entirely

Topical ivermectin was formulated for a different purpose: local action on the skin, with minimal absorption into the bloodstream. The FDA approved a 1% ivermectin cream in 2014 for inflammatory lesions of rosacea, a chronic facial skin condition linked in part to overgrowth of Demodex mites. Two randomized, double-blind, vehicle-controlled Phase 3 trials, published around 2014 in dermatology literature, found once-daily application over 12 weeks produced significantly greater reduction in inflammatory lesion counts compared with the inactive vehicle cream, with a good tolerability profile. This is a case where the topical route is not a weaker version of the oral drug — it is the correct tool for a localized problem, delivering the drug where the mites live without exposing the rest of the body to a systemic dose it does not need.

A separate 0.5% ivermectin lotion was approved in 2012 for head lice. A trial published in the New England Journal of Medicine around that time found that a single ten-minute application, without the nit-combing traditionally required by other treatments, produced substantially higher rates of lice-free outcomes compared with a placebo lotion. Again, the lotion's job is purely local — killing lice and their eggs on contact on the scalp — and it was never designed or tested to treat worms or mites elsewhere in the body.

Ivermectin cream and lotion are typically white, smooth, and odorless or faintly medicinal in smell, dispensed in a pump or tube rather than as tablets. Because the FDA-approved brand exclusivity period has lapsed for these formulations, generic topical ivermectin is now more widely available, and prices have come down from their original brand-only levels, though topical formulations generally remain more expensive per course than a short round of generic oral tablets, reflecting the cost of the vehicle base and manufacturing process rather than the ivermectin itself.

Why the Same Drug Behaves Differently by Route

The central lesson here is pharmacokinetic, not marketing. Oral ivermectin is absorbed through the intestinal wall, is enhanced by a fatty meal, undergoes hepatic metabolism largely via the CYP3A4 enzyme pathway, and distributes through the bloodstream to tissues throughout the body — which is exactly what is needed to reach a migrating Strongyloides larva or a microfilaria beneath the skin in onchocerciasis. Topical cream and lotion, by contrast, are designed to stay largely in the outer skin layers where they are applied; systemic absorption is deliberately minimized, both to concentrate the drug where the parasite or mite actually lives and to avoid unnecessary systemic exposure.

This is why one formulation cannot simply substitute for another:

None of this means one form is "stronger" or "weaker" than another in a general sense — each was matched to a specific biological target, and good prescribing respects that matching rather than treating ivermectin as one interchangeable substance.

Off-Label Use, COVID-19, and the Limits of Current Evidence

Ivermectin drew broad public attention during the COVID-19 pandemic as a potential antiviral treatment, based initially on laboratory (in vitro) studies showing it could inhibit viral replication in cell cultures at concentrations far higher than what is achievable in the human body at approved doses. That gap between a cell-culture finding and a clinically meaningful human effect is significant, and it is the reason in vitro results should never be read as proof of a treatment effect in people.

Since then, ivermectin has been studied directly in humans for COVID-19 in several randomized controlled trials. The ACTIV-6 trial, a large NIH-funded, placebo-controlled study published in JAMA in 2022, found that oral ivermectin at approved doses did not meaningfully improve time to recovery in outpatients with mild to moderate COVID-19 compared with placebo. Ivermectin remains not FDA-approved for the prevention or treatment of COVID-19 at the time of writing. Patients considering off-label use of any approved drug have every right to discuss the existing evidence honestly with their own physician and make an informed decision together — that is the proper exercise of informed consent — but that conversation should be grounded in what the human trials actually show, not in cell-culture data or anecdote alone.

Veterinary Products Are a Different Category

Ivermectin is also formulated as veterinary paste, pour-on solution, and injectable for livestock, horses, and companion animals, at concentrations and in vehicle bases suited to animal species and weight ranges that can be enormously larger than a human's. These products are not manufactured, tested, or regulated for human dosing, and they often use different inactive ingredients. Poison control centers in the United States recorded a marked increase in calls related to human ingestion of veterinary ivermectin products during periods of pandemic-era interest in the drug, with reported cases of nausea, vomiting, low blood pressure, confusion, and, in some instances, more serious neurological symptoms. Responsible stewardship of one's own health means using a human formulation, at a human dose, prescribed by a licensed clinician who knows your weight, kidney and liver function, and other medications — not adapting an animal product out of convenience or cost.

Key takeaway: Ivermectin's tablets, cream, and lotion were each engineered for a specific parasite in a specific location in the body, so choosing the right formulation — at the right dose, prescribed by a physician who knows your full medical picture — determines whether the treatment actually works.